This is the authors' abstract. We don't add key points for this paper.
Thyroid-associated ophthalmopathy, also known as Graves’ ophthalmopathy, is a proliferative disorder of the orbit of the eye with an autoimmune etiology. Disease arises from the enlargement of the extraocular muscles, adipose, and the associated connective tissue that, if untreated, leads to a compressive optic neuropathy and blindness. In Graves’ disease, hyperthyroidism develops from autoantibodies directed against the thyroid-stimulating hormone receptor (TSHR) expressed on the follicular endothelial cells of the thyroid gland. Anti-TSHR autoantibodies stimulate the excessive production of thyroid-stimulating hormone, which in turn leads to the clinical manifestations of hyperthyroidism: thyroid gland enlargement, weight loss, tremor, palpitations, dermopathy, and, in up to 30% of subjects, autoimmune inflammation of the orbital structures (1). In PNAS, Fernando et al. provide evidence for a proximal and central role for the circulating fibrocyte in Graves’ ophthalmopathy pathogenesis (2). The autoimmune diseases comprise at least 100 nosologically distinct entities that afflict as many as 5% of the US population (3). Autoimmunity can be organ specific, as in the case of an autoantibody attack against the neuromuscular junction in myasthenia gravis, or systemic in nature or manifestations, as in the immune complex pathology of systemic lupus erythematosus. The presence of anti-TSHR antibodies in nearly all patients with Graves’ ophthalmopathy together with the correlation between their circulating levels and both the clinical features and prognosis … [↵][1] 1Email: richard.bucala{at}yale.edu. [1]: #xref-corresp-1-1
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Richard Bucala (2022) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: